International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 10, October 2025 **ijppr.humanjournals.com** ISSN: 2349-7203

Botulinum Neurotoxin in Medicine: From Basic Mechanisms to Clinical Practice and Emerging Indications

Dr. Snehashis Singha*, Dr. Rajasree Majumder[2]

* Resident Doctor, Department of Pharmacology and Therapeutics, King George's Medical University (KGMU), Lucknow, Uttar Pradesh, India
[2] Resident Doctor, Department of Microbiology, King George's Medical University (KGMU), Lucknow, Uttar Pradesh, India

Received: 9 September 2025 Revised: 29 September 2025 Accepted: 10 October 2025

ABSTRACT:

Background: Botulinum neurotoxin (BoNT), a potent exotoxin produced by *Clostridium botulinum*, has evolved from a cause of paralytic botulism to a cornerstone of modern therapeutics. Through advances in molecular pharmacology and controlled dosing, this once-lethal toxin has been redefined as a versatile and safe biotherapeutic agent—an outstanding example of translational medicine bridging microbiology and clinical pharmacology. **Objective:** To provide an integrated overview of the mechanisms, clinical applications, safety profile, limitations, and future perspectives of BoNT therapy, emphasizing its translational continuum from toxin to therapy. **Summary:** BoNT acts by selective binding to cholinergic nerve terminals and cleavage of SNARE proteins, thereby inhibiting acetylcholine release and inducing reversible neuromuscular blockade. Beyond its motor effects, BoNT modulates sensory and autonomic neurotransmission, accounting for benefits in chronic migraine, neuropathic pain, and hyperhidrosis. Among its serotypes, BoNT/A remains the gold standard owing to prolonged duration, better tolerability, and broad FDA-approved indications, while BoNT/B serves as an alternative for antibody-resistant cases. Strong evidence from randomized controlled trials supports its efficacy in dystonia, spasticity, and chronic migraine; however, studies in pain, vascular, and psychiatric indications remain limited by small sample sizes and methodological heterogeneity. Gaps persist in comparative serotype trials, long-term safety data, and cost-effectiveness analyses. **Conclusion:** BoNT epitomizes the transformation of a bacterial toxin into a precision neuromodulator. Future research directed toward recombinant toxin engineering, extended-duration formulations, targeted delivery, and biomarker-based patient selection will expand its therapeutic spectrum. The journey of BoNT from toxin to therapy stands as a paradigm of translational pharmacology and clinical innovation.

Keywords: Botulinum toxin; Myofascial pain; Temporomandibular disorders; Hyperhidrosis; Vascular disorders; Translational therapeutics

INTRODUCTION

Botulinum toxin, produced by the anaerobic bacterium *Clostridium botulinum*, Figure 1. is recognized as the most potent naturally occurring neurotoxin. It causes botulism, a paralytic disease historically linked to foodborne outbreaks from improperly preserved meat and vegetables. Early descriptions of "sausage poisoning" in 18th and 19th century Europe reflected the lethal nature of the toxin, which remained for decades a public health threat rather than a therapeutic consideration. (1)



Figure 1. Image Clostridium botulinum source: Centers for Disease Control and Prevention. Botulism — Clinical Features [Internet]. Atlanta (GA): CDC; 2024. Available from: https://www.cdc.gov/botulism/clinical-features.html

The paradigm shift occurred in the mid-20th century, when pioneering work demonstrated that the toxin could be safely harnessed in extremely small, controlled doses. The breakthrough in medical application came from ophthalmology: Alan B. Scott first used botulinum toxin to treat strabismus in the late 1970s. Its success led to wider investigation in conditions characterized by abnormal muscle activity. By the early 1980s, botulinum toxin type A received approval for blepharospasm and strabismus, laying the foundation for its therapeutic role.(2)

The biological action of botulinum toxin is highly specific. It binds to presynaptic cholinergic nerve terminals, undergoes internalization, and cleaves SNARE proteins critical for synaptic vesicle fusion. The result is inhibition of acetylcholine release, producing localized, reversible chemo denervation of targeted muscles or glands. This unique mechanism explains its clinical utility: muscle overactivity can be suppressed, abnormal glandular secretions reduced, and sensory neurotransmission modulated. Over time, the toxin's therapeutic potential has expanded from purely motor conditions to disorders involving pain, autonomic dysfunction, and even cosmetic enhancement.(3)

Today, botulinum toxin is firmly established in neurology for dystonia, spasticity, hemifacial spasm, and chronic migraine. In pain medicine, it has been evaluated for myofascial pain, temporomandibular disorders, trigeminal neuralgia, and neuropathic syndromes. Dermatology and cosmetic medicine rely on it for management of facial rhytides and hyperhidrosis, while vascular and reconstructive surgery employ it for ischemic digits and scleroderma-related vasospasm. (4–6) Despite its proven efficacy, controversies remain regarding patient selection, trial heterogeneity, and long-term safety. Nonetheless, botulinum toxin represents a remarkable example of translational medicine, where a feared poison has been transformed into a cornerstone of therapy. With ongoing research into engineered molecules, extended-duration formulations, and biomarker-guided precision medicine, its scope is expected to expand further in the coming years.

Mechanism of Action of Botulinum Toxin

Botulinum toxin (BoNT) exerts its pharmacological action in a highly specific and stepwise manner, making it unique among therapeutic agents. The toxin molecule consists of a heavy chain (100 kDa) responsible for receptor binding and translocation, and a light chain (50 kDa) that functions as a zinc-dependent endopeptidase. 3d structure of the botulium toxin is shown in Figure 2. The sequence of action as follows: (see Table 1)



Figure 2. 3d ribbon model of botulinum neurotoxin serotype A (botox) from PDB 3BTA *(7)*

1. Specific Binding to Presynaptic Membranes

The heavy chain binds selectively to cholinergic presynaptic terminals, particularly at the neuromuscular junction and autonomic cholinergic synapses. Dual receptor recognition occurs via:

- Polysialogangliosides (GT1b, GD1a, GD1b) on the neuronal membrane.

- Synaptic vesicle glycoproteins (SV2, synaptotagmin) exposed during vesicle recycling.

This dual binding explains the high specificity of BoNT for cholinergic neurons while sparing other synaptic systems. (3)

2. Endocytosis and Internalization

The BoNT–receptor complex undergoes clathrin-mediated endocytosis, forming an acidic endocytic vesicle. The acidic pH triggers a conformational change in the heavy chain's translocation domain, enabling the formation of a channel through which the light chain traverses the vesicular membrane. (1)

3. Translocation of the Light Chain

Reduction of the disulfide bond linking the heavy and light chains allows the light chain to enter the neuronal cytoplasm. The light chain is catalytically active and persists for 3–6 months, which explains the prolonged clinical effect of a single injection. (2)

4. Cleavage of SNARE Proteins

The SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex is essential for vesicle docking and neurotransmitter release. See in Figure 3.

- BoNT/A and BoNT/E cleave SNAP-25.

- BoNT/B, D, F, and G cleave synaptobrevin (VAMP).

- BoNT/C cleaves syntaxin and SNAP-25.

Cleavage of these proteins prevents fusion of acetylcholine-containing vesicles with the presynaptic membrane, thereby blocking neurotransmitter release.



Figure 3. The mechanisms of BoNT/A action at the synapse. *(8)*

5. Functional Consequences

The result is flaccid paralysis of the targeted muscle due to lack of acetylcholine at the neuromuscular junction. In autonomic sites, the same mechanism inhibits cholinergic sympathetic and parasympathetic transmission, explaining efficacy in hyperhidrosis, hypersalivation, and glandular disorders.

6. Sensory and Analgesic Mechanisms

Emerging evidence indicates that BoNT also inhibits release of substance P, calcitonin gene-related peptide (CGRP), and glutamate from peripheral nociceptors. This neuromodulatory effect contributes to analgesia in chronic pain syndromes and migraine, broadening its role beyond motor disorders .(9,10)

Table 1. Summary of Mechanism of Action of Botulinum Toxin

Step	***Structural Component***	***Molecular Target/Pathway***	***Detailed Mechanism***	***Functional/Clinical Outcome***
Binding (8,11)	Heavy chain (100 kDa)	Polysialogangliosides (GT1b, GD1a, GD1b), Synaptic vesicle glycoprotein SV2, Synaptotagmin	Dual receptor recognition ensures selective binding to cholinergic presynaptic terminals	High neuronal specificity, sparing non-cholinergic systems
Endocytosis (12)	Heavy chain (binding domain)	Clathrin-mediated endocytosis	Formation of endocytic vesicle containing BoNT-receptor complex	Entry of toxin into neuron without systemic diffusion
Translocation (13)	Heavy chain (translocation domain) & disulfide bond cleavage	Acidification of vesicle	Heavy chain forms channel → light chain traverses into cytosol	Enables catalytic activity of light chain
Enzymatic cleavage (14)	Light chain (50 kDa zinc-dependent endopeptidase)	SNARE proteins: SNAP-25 (BoNT/A,E), Synaptobrevin/VAMP (BoNT/B,D,F,G), Syntaxin (BoNT/C)	Cleavage prevents vesicle docking and fusion with presynaptic membrane	Complete inhibition of acetylcholine release
Functional effect (15)	Local NMJ and autonomic synapses	Acetylcholine blockade	Flaccid paralysis of muscle, inhibition of glandular secretions	Reversible chemodenervation for 3–6 months
Sensory /Analgesic effects (16)	Peripheral nociceptors	Substance P, CGRP, Glutamate release	Inhibition of nociceptive neurotransmitters and neurogenic inflammation	Analgesia in migraine, neuropathic pain, TMD

Clinical Applications

The versatility of BoNT has led to its adoption across neurology, pain medicine, dermatology, reconstructive surgery, and experimental specialties. (see Table 2)

1. Neurology

a. Dystonia and Spasticity

- BoNT/A is first-line therapy for focal dystonias (cervical dystonia, blepharospasm, hemifacial spasm).
- Multiple RCTs confirm significant improvements in abnormal posture, pain, and disability scores.(15)

- Spasticity from stroke, multiple sclerosis, cerebral palsy, and spinal cord injury also responds well, with improved function and reduced caregiver burden. (12)

b. Chronic Migraine

- The PREEMPT program established BoNT/A as an evidence-based therapy for chronic migraine.
- Benefits include reduction in headache days, improved patient-reported outcomes, and sustained efficacy over repeated cycles.(17)

2. Pain Medicine

a. Myofascial Pain and Temporomandibular Disorders (TMD)

- BoNT/A injections reduce muscle hyperactivity and associated pain.
- Song et al. (2007) reported significant improvements in TMD-related pain and function.(18)
- Ernberg et al. (2011) confirmed efficacy in persistent myofascial TMD pain through a multicenter RCT.

b. Neuropathic Pain Syndromes

- Trigeminal neuralgia: Bohluli et al. (2011) demonstrated benefit in refractory cases.(19)
- Post-herpetic neuralgia: Liu et al. (2006) reported significant pain reduction.(20)
- Analgesia is likely mediated through suppression of neuropeptide release from sensory terminals.

c. Musculoskeletal Pain

- Evidence from RCTs suggests efficacy in chronic neck pain and upper back myofascial pain syndrome. (21,22)
- Meta-analysis supports BoNT/A in chronic musculoskeletal pain but highlights variability across trials. (23)

3. Dermatology and Aesthetic Medicine

- Cosmetic use: cornerstone in treating facial rhytides (glabellar lines, crow's feet, forehead lines).
- Hyperhidrosis: FDA-approved for axillary hyperhidrosis; reduces sweat by blocking cholinergic sympathetic transmission to eccrine glands.
- Also used in palmar and plantar hyperhidrosis, with high patient satisfaction. (2)

4. Vascular and Reconstructive Surgery

- BoNT/A improves perfusion in ischemic digits and scleroderma-related vasospasm by inhibiting sympathetic vasoconstrictor activity.
- Neumeister et al. (2009) demonstrated pain relief and healing in patients with ischemic digits resistant to conventional therapy. (5)

5. Emerging Indications

- Psychiatry: Trials report improvement in depression with glabellar injections.
- Urology: promising results in overactive bladder and benign prostatic hyperplasia
- Gastroenterology: role in achalasia, refractory anal fissure, and irritable bowel syndrome.

- Other neurological disorders: small studies suggest utility in refractory headache types, trigeminal pain, and peripheral neuropathies. (10)

Table 2. Clinical Applications of Botulinum Toxin Across Specialties

Specialty	*Indication*	*Evidence Base (Key Trials/Reviews)*	*Clinical Outcome*
Neurology (12,13,15,17)	Cervical dystonia	Multiple RCTs, FDA-approved	Improves abnormal posture, pain, function
	Blepharospasm/Hemifacial spasm	Long-term clinical experience	Reduced spasms, sustained benefit
	Spasticity (stroke, MS, CP, SCI)	Multicenter RCTs	Reduced tone, improved caregiver ease
	Chronic migraine	PREEMPT I & II trials	↓ Headache days, improved QoL
Pain Medicine (24–27)	Temporomandibular disorders	Song et al., 2007; Ernberg et al., 2011	↓ Pain, improved mouth opening
	Myofascial pain	Meta-analyses, variable results	Reduction in trigger point pain
	Neuropathic pain (Trigeminal neuralgia, PHN)	Bohluli et al., 2011; Liu et al., 2006	↓ Pain scores in refractory cases
	Musculoskeletal pain (chronic neck/back pain)	Wheeler et al., 2001; Zhang et al., 2011	Mixed evidence; subgroup benefit
Dermatology / Aesthetic Medicine (13)	Hyperhidrosis (axillary, palmar, plantar)	FDA-approved	↓ Sweat by 80–90% for 6–9 months
	Facial rhytides (glabellar lines, crow's feet, forehead)	Multiple RCTs	Improved cosmetic appearance
Vascular / Reconstructive Surgery (28,29)	Ischemic digits (scleroderma, vasospasm)	Neumeister et al., 2009	Improved perfusion, pain relief
	Raynaud's phenomenon	Herrick, 2008	Symptomatic relief, ulcer healing
Emerging / Experimental (13)	Depression	Pilot studies, small RCTs	Mood improvement with glabellar injection
	Overactive bladder, BPH	Phase II–III trials	↓ Urgency, ↑ bladder capacity
	Gastrointestinal disorders (achalasia, anal fissure, IBS)	Case series, early RCTs	Improved motility symptoms

Safety Profile and Adverse Effects

When administered by trained clinicians at recommended doses, botulinum toxin is considered safe and well-tolerated. Its safety stems from its localized, reversible action, with systemic effects being exceedingly rare. However, adverse events (AEs) can occur and are generally categorized as **pharmacologic, injection-related, immunogenic, or population-specific**.

- **Pharmacologic effects:** unintended muscle weakness due to local spread (e.g., eyelid ptosis after periocular injection; dysphagia or neck weakness after cervical injection). These events are dose-related and self-limiting.
- **Injection-related effects:** pain, bruising, erythema, or edema at injection sites; occasional headaches or local infections have been reported. (6,30)
- **Immunogenicity:** repeated high-dose or short-interval injections can rarely induce neutralizing antibodies, leading to secondary non-response. Modern purified formulations have reduced this risk.
- **Population-specific risks:** patients with neuromuscular junction disorders (e.g., myasthenia gravis) may experience exaggerated systemic weakness. Dysphagia and respiratory compromise are reported in high-dose cervical dystonia therapy. (31) Use in pregnancy and lactation is generally avoided due to insufficient safety data.

Overall, most adverse events are mild, transient, and preventable with careful dosing, appropriate injection technique, and patient selection. (see Table 3)

Table 3. Safety Profile and Limitations of Botulinum Toxin Therapy

Category	*Adverse Effect / Limitation*	*Mechanism*	*Clinical Impact*	*Mitigation Strategy*
Pharmacological (15,28)	Local weakness (ptosis, diplopia, dysphagia, neck weakness)	Local spread of toxin	Transient disability	Dose adjustment, injection technique
	Systemic weakness (rare)	Unintended diffusion	Risk in neuromuscular disorders	Avoid in MG/ALS
Injection-related (24)	Pain, bruising, erythema, infection	Needle trauma, technique	Minor, self-limiting	Asepsis, fine needles
Immunogenicity (32)	Neutralizing antibodies → secondary non-response	Repeated high-dose, short-interval injections	Loss of efficacy	Use purified formulations, spacing ≥3 months
Special Populations (12,13)	Pregnancy/lactation	Unknown fetal safety	Avoid use	Restrict to emergencies
	Pediatric use (off-label)	Limited data	Safety concerns	Specialist supervision
Economic (27)	High treatment cost	Complex manufacturing	Limited access in LMICs	Health-policy subsidy, biosimilars
Controversies (25)	Variable efficacy in pain syndromes	Trial heterogeneity, poor standardization	Inconsistent results	Standardize protocols, stratify subgroups

Limitations and Controversies

Despite widespread adoption, several challenges remain:

1. **Variable efficacy**: While dystonia and migraine have strong evidence, results in musculoskeletal and myofascial pain are inconsistent.
2. **Methodological issues**: Lack of standardized injection techniques, inconsistent outcome measures, and heterogeneous patient populations complicate interpretation.
3. **Antibody-related failures**: Although rare, immunogenic resistance can cause treatment non-response, raising concerns in long-term therapy. (16)
4. **Off-label use**: Expanding indications in psychiatry, gastroenterology, and urology raise regulatory and ethical debates.
5. **Cost-effectiveness**: BoNT remains expensive, limiting access in resource-poor settings. Favorable cost–utility has been shown in migraine and dystonia but is less clear in other disorders.

Critical Discussion: Comparative Insights and Evidence Gaps

Although both botulinum neurotoxin type A (BoNT/A) and type B (BoNT/B) share a common molecular mechanism—blocking acetylcholine release through SNARE-protein cleavage—they differ significantly in pharmacologic and clinical profiles. BoNT/A cleaves SNAP-25 and generally produces a longer duration of action (approximately 12–16 weeks), whereas BoNT/B targets synaptobrevin (VAMP) and exhibits faster onset but shorter effect (8–12 weeks). BoNT/B formulations tend to cause more autonomic adverse effects such as dry mouth and dysphagia due to broader cholinergic binding, reflecting lower receptor specificity. Consequently, BoNT/A remains the preferred agent for most therapeutic and cosmetic indications, while BoNT/B serves as an alternative in BoNT/A-resistant cases or when antibody-mediated non-response occurs. Comparative clinical data are limited. Randomized controlled trials directly comparing the two serotypes are scarce, and most evidence is derived from independent single-arm studies or small crossover trials. In cervical dystonia, both serotypes achieve comparable symptom reduction, yet BoNT/A provides longer inter-injection intervals and better tolerability. In chronic migraine, only BoNT/A has Level A evidence from large PREEMPT trials; robust data for BoNT/B are lacking. For pain and autonomic disorders, heterogeneity of study design, dosage, and outcome measures precludes definitive conclusions regarding relative efficacy.

The strength of evidence across indications remains uneven. High-quality randomized controlled trials (RCTs) and meta-analyses strongly support BoNT/A use in focal dystonias, spasticity, and migraine, whereas data for neuropathic, musculoskeletal, and vascular disorders are based mainly on small open-label or pilot studies. Many pain trials suffer from small sample sizes, short follow-up, and non-standardized outcome scales, limiting reproducibility. Placebo effects and inter-individual variability in injection technique further confound interpretation. Few studies include head-to-head comparison of different commercial formulations (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA), making dose equivalence uncertain. Another major limitation lies in the paucity of long-term safety data and pharmacoeconomic analyses. Although immunogenicity rates have decreased with purified formulations, neutralizing antibody formation remains a concern in high-dose or frequent use. Additionally, most studies exclude vulnerable populations such as children, elderly, and pregnant women, leading to gaps in evidence-based dosing for these groups. Real-world registries and post-marketing surveillance are needed to evaluate cumulative safety and cost-effectiveness, particularly in low- and middle-income settings.

In summary, while BoNT/A dominates current clinical practice due to its favorable efficacy–safety balance, BoNT/B offers an important alternative in resistant cases. Future research should prioritize large, multicenter RCTs comparing serotypes, standardized outcome metrics for pain and autonomic disorders, and biomarker-driven patient selection to refine individualized therapy. Addressing these evidence gaps will strengthen the translational continuum from toxin biology to precision neurotherapeutics.

Future Directions

Research is focused on optimizing and expanding the clinical potential of botulinum toxin:

- **Novel formulations:** engineered long-acting serotypes and complex-free preparations promise longer efficacy with reduced immunogenicity.(16,33)
- **Expanding indications:** studies explore roles in fibromyalgia, visceral pain, major depressive disorder, overactive bladder, and benign prostatic hyperplasia. (26)
- **Engineered toxins:** recombinant variants with tailored receptor specificity and pharmacokinetics are under development.
- **New delivery systems:** advances include ultrasound-guided injections, topical and intradermal formulations, and site-specific targeting. (34)
- **Personalized medicine:** biomarker discovery and pharmacogenomic approaches may allow identification of responders, enabling precision therapy.

Conclusion

The translational continuum of BoNT, from bacterial toxin to precision biotherapeutic is visually summarized below (Graphical Summary, see Figure 4). It highlights how fundamental microbiological discovery evolved into a multifaceted clinical tool bridging neurology, dermatology, and pain medicine.



Figure 4. Graphical Summary. Translational Journey of Botulinum Neurotoxin (BoNT): From Microbial Toxin to Clinical Therapy. *Created by using Mermaid (https://mermaid.js.org).*

This schematic summarizes the transformation of *Clostridium botulinum* neurotoxin from bacterial production to therapeutic innovation. Through purification and precise dosing, BoNT acts at cholinergic terminals to block acetylcholine release, resulting in targeted modulation of muscle tone, pain, glandular secretion, vascular tone, and cosmetic relaxation. These mechanistic outcomes underpin its diverse clinical applications across neurology, pain medicine, dermatology, vascular medicine, and psychiatry.
Botulinum neurotoxin exemplifies translational pharmacology, the transformation of a potent bacterial poison into a precise neuromodulator with broad therapeutic scope. Its mechanism-based versatility, safety profile, and adaptability across specialties underscore its clinical and scientific significance. While robust evidence supports BoNT/A for dystonia, spasticity, and migraine, limited data for pain, vascular, and psychiatric disorders warrant well-designed multicenter randomized trials. Comparative serotype studies, pharmacogenomic profiling, and long-term safety analyses are key priorities.

Future innovation lies in recombinant toxin engineering, extended-duration formulations, and targeted delivery systems that align therapy with molecular pathophysiology. The journey of BoNT from *toxin to therapy* stands as a paradigm of how microbiological discovery can reshape modern pharmacotherapy and precision medicine.

REFERENCES

1. Setler PE. Therapeutic Use of Botulinum Toxins: Background and History. Clin J Pain. 2002 Nov;18(Supplement):S119–24.
2. Nigam P, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55(1):8.
3. Brin MF, Burstein R. Botox (onabotulinumtoxinA) mechanism of action. Medicine. 2023 Jul 1;102(S1):e32372.

4. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program. Headache: The Journal of Head and Face Pain. 2010 Jun;50(6):921–36.
5. Neumeister MW, Chambers CB, Herron MS, Webb K, Wietfeldt J, Gillespie JN, et al. Botox Therapy for Ischemic Digits. Plast Reconstr Surg. 2009 Jul;124(1):191–201.
6. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study. Pain. 2011 Sep;152(9):1988–96.
7. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998 Oct;5(10):898–902.
8. Brin MF, Burstein R. Botox (onabotulinumtoxinA) mechanism of action. Medicine. 2023 Jul 1;102(S1):e32372.
9. Arezzo JC. Possible Mechanisms for the Effects of Botulinum Toxin on Pain. Clin J Pain. 2002 Nov;18(Supplement):S125–32.
10. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009 Jan;141(1):60–9.
11. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl. 1997;6:S129-45.
12. Setler PE. Therapeutic Use of Botulinum Toxins: Background and History. Clin J Pain. 2002 Nov;18(Supplement):S119–24.
13. Nigam P, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55(1):8.
14. Arezzo JC. Possible Mechanisms for the Effects of Botulinum Toxin on Pain. Clin J Pain. 2002 Nov;18(Supplement):S125–32.
15. Lew MF. Review of the FDA-Approved Uses of Botulinum Toxins, Including Data Suggesting Efficacy in Pain Reduction. Clin J Pain. 2002 Nov;18(Supplement):S142–6.
16. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009 Jan;141(1):60–9.
17. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program. Headache: The Journal of Head and Face Pain. 2010 Jun;50(6):921–36.
18. Song P, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis. 2007 May 18;13(3):253–60.
19. Bohluli B, Motamedi MHK, Bagheri SC, Bayat M, Lassemi E, Navi F, et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2011 Jan;111(1):47–50.
20. Liu HT, Tsai SK, Kao MC, Hu JS. Botulinum Toxin A Relieved Neuropathic Pain in a Case of Post-Herpetic Neuralgia. Pain Medicine. 2006 Jan 1;7(1):89–91.
21. Wheeler AH, Goolkasian P, Gretz SS. Botulinum toxin A for the treatment of chronic neck pain. Pain. 2001 Dec;94(3):255–60.
22. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport®) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study. Pain. 2006 Nov;125(1):82–8.
23. Zhang T, Adatia A, Zarin W, Moitri M, Vijenthira A, Chu R, et al. The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis. Inflammopharmacology. 2011 Feb 13;19(1):21–34.
24. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study. Pain. 2011 Sep;152(9):1988–96.
25. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport®) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study. Pain. 2006 Nov;125(1):82–8.
26. Bohluli B, Motamedi MHK, Bagheri SC, Bayat M, Lassemi E, Navi F, et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2011 Jan;111(1):47–50.
27. Zhang T, Adatia A, Zarin W, Moitri M, Vijenthira A, Chu R, et al. The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis. Inflammopharmacology. 2011 Feb 13;19(1):21–34.
28. Herrick A. Diagnosis and Management of Scleroderma Peripheral Vascular Disease. Rheumatic Disease Clinics of North America. 2008 Feb;34(1):89–114.
29. Neumeister MW, Chambers CB, Herron MS, Webb K, Wietfeldt J, Gillespie JN, et al. Botox Therapy for Ischemic Digits. Plast Reconstr Surg. 2009 Jul;124(1):191–201.
30. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of Botulinum Toxin in Treating Myofascial Pain in Bruxers: A Controlled Placebo Pilot Study. CRANIO®. 2008 Apr 31;26(2):126–35.
31. Herrick A. Diagnosis and Management of Scleroderma Peripheral Vascular Disease. Rheumatic Disease Clinics of North America. 2008 Feb;34(1):89–114.
32. Qerama E, Fuglsang-Frederiksen A, Jensen TS. The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol. 2010 Oct;23(5):602–10.

33. Berger MM, Sareban M, Schiefer LM, Swenson KE, Treff F, Schäfer L, et al. Effects of acetazolamide on pulmonary artery pressure and prevention of high-altitude pulmonary edema after rapid active ascent to 4,559 m. J Appl Physiol. 2022 Jun 1;132(6):1361–9.
34. Chen Y, Tsai CH, Bae TH, Huang CY, Chen C, Kang YN, et al. Effectiveness of Botulinum Toxin Injection on Bruxism: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Aesthetic Plast Surg. 2023 Apr 24;47(2):775–90.

How to cite this article:
Dr. Snehashis Singha et al. Ijppr.Human, 2025; Vol. 31 (10): 33-43.

Conflict of Interest Statement: All authors have nothing else to disclose.

Corresponding Author: **Dr. Snehashis Singha**

Author Affiliation: **Resident Doctor**

Author Address/Institute Address: **Department of Pharmacology and Therapeutics, King George's Medical University (KGMU), Lucknow, Uttar Pradesh, India, 226003**

Author Name: **Dr. Rajasree Majumder**

Author Affiliation: **Resident Doctor**

Author Address/Institute Address: **Department of Microbiology, King George's Medical University (KGMU), Lucknow, Uttar Pradesh, India, 226003**